These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34171438)

  • 21. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
    Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
    J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
    Jeng WJ; Chien RN; Liaw YF
    Hepatology; 2024 Apr; 79(4):E109-E110. PubMed ID: 37906680
    [No Abstract]   [Full Text] [Related]  

  • 23. [Results of 2 years of interferon treatment in HBeAg positive chronic hepatitis B].
    Hu LH; Long XZ; Tang CL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):940-1. PubMed ID: 20038338
    [No Abstract]   [Full Text] [Related]  

  • 24. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B.
    Jun BG; Lee SH; Kim HS; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Kim YD; Cheon GJ
    Korean J Gastroenterol; 2016 Jan; 67(1):28-34. PubMed ID: 26809629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients-Functional cure unlikely.
    Cho JY; Sohn W; Paik YH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Park CG
    J Viral Hepat; 2020 Sep; 27(9):951-954. PubMed ID: 32338803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients.
    Liaw YF; Jeng WJ; Chang ML
    Gastroenterology; 2018 Jun; 154(8):2280-2281. PubMed ID: 29746811
    [No Abstract]   [Full Text] [Related]  

  • 29. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study.
    Hadziyannis S; Alexopoulou A; Papakonstantinou A; Petraki K; Manesis E
    J Viral Hepat; 2000 May; 7(3):235-40. PubMed ID: 10849267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients.
    Yang J; Chen J; Ye P; Jin L; Wu W; Sheng G; Li LJ
    J Transl Med; 2014 Jun; 12():183. PubMed ID: 24962263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
    Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B.
    Chi H; Hansen BE; Yim C; Arends P; Abu-Amara M; van der Eijk AA; Feld JJ; de Knegt RJ; Wong DK; Janssen HL
    Aliment Pharmacol Ther; 2015 May; 41(9):867-76. PubMed ID: 25752878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.
    Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2013 Aug; 48(8):930-41. PubMed ID: 23065021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stopping Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.
    Liaw YF
    Gastroenterology; 2020 Sep; 159(3):1186. PubMed ID: 32433984
    [No Abstract]   [Full Text] [Related]  

  • 38. Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy.
    Li J; Sun X; Fang J; Wang C; Han G; Ren W
    Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):635-643. PubMed ID: 28438570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Mohamadnejad M
    Arch Iran Med; 2006 Jan; 9(1):90-2. PubMed ID: 16649389
    [No Abstract]   [Full Text] [Related]  

  • 40. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.